To look at revenue earnings in perspective...as of
Post# of 148123
(Total Views: 447)
Posted On: 05/04/2021 5:48:55 PM
Re: crazyjogger925 #88980
To look at revenue earnings in perspective...as of July/2020;
# 1...Pfizer earnings at $51,750 Billion...in contrast to
#10 BMS earnings at $26,145 Billion. REVLIMID #3 in the world Cancer drug...with earnings of 12.15 Billion..almost 46.47% of total earnings....A caveat;
Warning label: Potential for Human Birth Defects displayed prominently on the container of 100 tablets..selling today for $750.00 EACH...a high price for a potential birth defect..anyone for Thalidimide?...10,000 babies born ..barely 3000 are living today.
The price of the product was raised to hit the aggressive revenue targets. According to a congressional probe...(did I say something about skeletons and closets)
BMS last year unveiled a (settlement..yes Lawyers) that allows East Indian generic firms to launch after March 2022.
BMS just recently received /scored two CAR-T approvals. They are in the early stages of key launches in Cancer indications. After March 2022...patents rights and that protection is gone. Pipelines fill and pipelines get emptied....and corruption is always in plain sight...yeah really.
# 1...Pfizer earnings at $51,750 Billion...in contrast to
#10 BMS earnings at $26,145 Billion. REVLIMID #3 in the world Cancer drug...with earnings of 12.15 Billion..almost 46.47% of total earnings....A caveat;
Warning label: Potential for Human Birth Defects displayed prominently on the container of 100 tablets..selling today for $750.00 EACH...a high price for a potential birth defect..anyone for Thalidimide?...10,000 babies born ..barely 3000 are living today.
The price of the product was raised to hit the aggressive revenue targets. According to a congressional probe...(did I say something about skeletons and closets)
BMS last year unveiled a (settlement..yes Lawyers) that allows East Indian generic firms to launch after March 2022.
BMS just recently received /scored two CAR-T approvals. They are in the early stages of key launches in Cancer indications. After March 2022...patents rights and that protection is gone. Pipelines fill and pipelines get emptied....and corruption is always in plain sight...yeah really.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼